Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.

Overview

This study aims to address the hypothesis that Lorazepam (an anticonvulsant) is as effective when given via the intranasal or buccal route as the intravenous route in terminating convulsions in children.

Full Title of Study: “Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2009

Detailed Description

Convulsions are common in children. Prompt treatment with an effective anticonvulsant reduces longterm morbidity and mortality. The use of intravenous lorazepam as first line therapy in acute childhood convulsions where venous access has been obtained is widely accepted in developed countries. However, intravenous access can be a problem out of hospital or in small children. Benzodiazepines such as Lorazepam have long been the mainstay of first line therapy for acute convulsions but there is insufficient clinical evidence as to the optimal mode of administration when venous access has failed. Lorazepam can be given via the intranasal and buccal route offering the potential to be as effective as intravenous lorazepam whilst being easier to administer and avoiding the need for intravenous cannulation. To date there are no large published studies that have evaluated the efficacy and safety of intranasal or buccal lorazepam compared to intravenous lorazepam in the treatment of acute convulsions. In this study we wish to address the urgent need to obtain randomized controlled data in treating acute convulsions in children using a drug and delivery system that is safe, effective and easy to use in our setting.

Interventions

  • Drug: Lorazepam
    • All doses 0.1mg/kg once, repeat after 10 minutes x1

Clinical Trial Outcome Measures

Primary Measures

  • Whether cessation of fit was achieved within ten minutes or not.

Secondary Measures

  • Frequency of additional drugs required to terminate presenting seizure
  • Frequency of cardio-respiratory side effects
  • Seizure recurrence within 24 hours of terminating the presenting seizure
  • Time from identification of a fitting child to cessation of fit.
  • Outcome of patients including any neurological sequelae at hospital discharge.

Participating in This Clinical Trial

Inclusion Criteria

children with acute generalized seizures, continuing for a minimum of 5 minutes, who have not received any anti-convulsant therapy within 1 hour of presentation. Exclusion Criteria:

Children who have received anticonvulsant treatment within 1 hour prior to assessment. Any child whose seizures cease following correction of hypoglycaemia. Children with a known adverse reaction to lorazepam.

Gender Eligibility: All

Minimum Age: 2 Months

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kamuzu University of Health Sciences
  • Provider of Information About this Clinical Study
    • Principal Investigator: Elizabeth Molyneux, Professor of Paediatircs – Kamuzu University of Health Sciences
  • Overall Official(s)
    • Elizabeth Molyneux, Principal Investigator, College of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.